References - Therapeutic Strategies in Cancer Biology and Pathology - page 252

Toffoli, S., Delaive, E., Dieu, M., Feron, O., Raes, M., Michiels, C., 2009. NDRG1 and
CRK-I/II are regulators of endothelial cell migration under intermittent hypoxia.
Angiogenesis 12, 339-354.
Toh, Y., Nicolson, G.L., 2009. The role of the MTA family and their encoded proteins in
human cancers: Molecular functions and clinical implications. Clin. Exp. Metastasis 26,
215-227.
Toh, Y., Pencil, S.D., Nicolson, G.L., 1994. A novel candidate metastasis-associated gene,
mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines.
cDNA cloning, expression, and protein analyses. J. Biol. Chem. 269, 22958-22963.
Toh, Y., Pencil, S.D., Nicolson, G.L., 1995. Analysis of the complete sequence of the novel
metastasis-associated candidate gene, mta1, differentially expressed in mammary adeno-
carcinoma and breast cancer cell lines. Gene 159, 97-104.
Tokuda, H., Kozawa, O., Uematsu, T., 2000. Basic fibroblast growth factor stimulates vascular
endothelial growth factor release in osteoblasts: divergent regulation by p42/p44 mito-
gen-activated protein kinase and p38 mitogen-activated protein kinase. J. Bone Mineral
Res. 15, 2371-2379.
Tomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Tomokuni, A., Kobayashi, S., et al., 2010.
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluoro-
uracil in hepatocellular carcinoma cells. Br. J. Cancer 103, 1617-1626.
Tommasi, S., Besaratinia, A., Wilczynski, S.P., Pfeifer, G.P., 2011. Loss of Rassf1a enhances
p53-mediated tumor predisposition and accelerates progression to aneuploidy. Oncogene
30, 690-700.
Torres, A., Torres, K., Paszkowski, T., Radej, S., Staskiewicz, G.J., Ceccaroni, M., et al. 2011.
Highly increased maspin expression corresponds with up-regulation of miR-21 in endo-
metrial cancer: a preliminary report. Int. J. Gynecol. Cancer 21, 8-14.
Toyoshima-Morimoto, F., Taniguchi, E., Nishida, E., 2002. Plk1 promotes nuclear transloca-
tion of human Cdc25C during prophase. EMBO J. 3, 341-348.
Trachtman, H., Fervenza, F.C., Gipson, D.S., Heering, P., Jayne, D.R.W., Peters, H.,
et al., 2011. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody,
in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79,
1236-1243.
Trakul, N., Menard, R.E., Schade, G.R., Qian, Z., Rosner, M.R., 2005. Raf kinase inhibi-
tory protein regulates Raf-1 but not B-Raf kinase activation. J. Biol. Chem. 280,
24931-24940.
Tremblay, M.R., Nevalainen, M., Nair, S.J., Porter, J.R., Castro, A.C., Behnke, M.L., et al.,
2008. Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog
pathway antagonists. J. Med. Chem. 51, 6646-6649.
Tremblay, M.R., Lescarbeau, A., Grogan, M.J., Tan, E., Lin, G., Austad, B.C., et al., 2009.
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J. Med.
Chem. 52, 4400-4418.
Tripathi, V., Popescu, N.C., Zimonjic, D.B., 2013. DLC1 induces expression of E-cadherin in
prostate cancer cells through Rho pathway and suppresses invasion. Oncogene, February
4, doi: 10.1038/onc.2013.7.
Trojan, J., Brieger, A., Raedle, J., Esteller, M., Zeuzem, S., 2000. 5'-CpG island methylation of
the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorec-
tal cancer. Gut 47, 272-276.
Tryndyak, V.P., Beland, F.A., Pogribny, I.P., 2010. E-cadherin transcriptional down-
regulation by epigenetic and microRNA-200 family alterations is related to mesen-
chymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer 126,
2575-2583.